Left ventricular remodeling: pathophysiology and treatment
- PMID: 14724719
Left ventricular remodeling: pathophysiology and treatment
Abstract
Left ventricular (LV) remodeling, which can result from myocardial damage or ventricular pressure or volume overload, has genomic, cellular, and interstitial components with associated changes in ventricular size, shape, wall thickness, and function. It is a process that is detectable and measurable clinically, generally progressive, and associated with adverse outcomes. However, it is amenable to intervention, prevention, or reversal. Following myocardial infarction (MI), LV remodeling is particularly likely in patients with transmural or anterior infarction and in those with failed reperfusion or LV failure. Infarct artery patency and neurohormonal blockade are key management considerations for prevention or reversal of LV remodeling. Combination treatment with angiotensin-converting enzyme inhibition and beta-blockade is of proven benefit following MI, improving LV remodeling and long-term outcomes.
Similar articles
-
Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction.Circulation. 2003 May 27;107(20):2559-65. doi: 10.1161/01.CIR.0000068340.96506.0F. Epub 2003 May 5. Circulation. 2003. PMID: 12732605 Clinical Trial.
-
[MRT assessment of metabolic and thrombolytic therapy effects on postinfarction left ventricular remodeling].Ter Arkh. 2006;78(9):38-43. Ter Arkh. 2006. PMID: 17076223 Clinical Trial. Russian.
-
Ventricular remodeling and its prevention in the treatment of heart failure.Curr Opin Cardiol. 1998 May;13(3):162-7. Curr Opin Cardiol. 1998. PMID: 9649938 Review.
-
New concepts in post-infarction ventricular remodeling.Rev Cardiovasc Med. 2003;4 Suppl 3:S3-12. Rev Cardiovasc Med. 2003. PMID: 14564229 Review.
-
Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction.J Card Fail. 2002 Dec;8(6 Suppl):S465-71. doi: 10.1054/jcaf.2002.129289. J Card Fail. 2002. PMID: 12555159 Review.
Cited by
-
Associations of Posthemodialysis Weights above and below Target Weight with All-Cause and Cardiovascular Mortality.Clin J Am Soc Nephrol. 2015 May 7;10(5):808-16. doi: 10.2215/CJN.10201014. Epub 2015 Apr 10. Clin J Am Soc Nephrol. 2015. PMID: 25862779 Free PMC article.
-
Disentangling the ultrafiltration rate-mortality association: the respective roles of session length and weight gain.Clin J Am Soc Nephrol. 2013 Jul;8(7):1151-61. doi: 10.2215/CJN.09460912. Epub 2013 Mar 14. Clin J Am Soc Nephrol. 2013. PMID: 23493384 Free PMC article.
-
Rapid ultrafiltration rates and outcomes among hemodialysis patients: re-examining the evidence base.Curr Opin Nephrol Hypertens. 2015 Nov;24(6):525-30. doi: 10.1097/MNH.0000000000000174. Curr Opin Nephrol Hypertens. 2015. PMID: 26371525 Free PMC article. Review.
-
Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality.Kidney Int. 2011 Jan;79(2):250-7. doi: 10.1038/ki.2010.383. Epub 2010 Oct 6. Kidney Int. 2011. PMID: 20927040 Free PMC article. Clinical Trial.
-
Glycaemic Control Impact on Renal Endpoints in Diabetic Patients on Haemodialysis.Int J Nephrol. 2015;2015:523521. doi: 10.1155/2015/523521. Epub 2015 Sep 20. Int J Nephrol. 2015. PMID: 26457201 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical